Institutional members access full text with Ovid®

Share this article on:

Cabergoline Therapy for Cushing Disease Throughout Pregnancy

Woo, Irene MD; Ehsanipoor, Robert M. MD

doi: 10.1097/AOG.0b013e31829e398a
Case Report

BACKGROUND: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms.

CASE: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate.

CONCLUSION: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

High-dose cabergoline can be used successfully to medically manage Cushing disease in pregnancy.

Department of Gynecology and Obstetrics and Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Corresponding Author: Irene Woo, MD, 600 North Wolfe St, Phipps 279, Baltimore MD, 21287, Tel: 610-69-8417, Email:

Financial Disclosure The authors did not report any potential conflicts of interest.

© 2013 by The American College of Obstetricians and Gynecologists.